Revolutionizing Tubal Patency Assessments: ExEm® Foam/HyFoSy Exhibition Debut at the 21st Annual Meeting of MRSi in Chicago, Illinois from June 8th to the 10th. Visit us at Booth #25.

RSVP for a One-on-One Meeting and Product Samples

(Limited inventory, First come-first served)

ExEm® Foam and the HyFoSy Procedure set a new standard for tubal patency assessments, revolutionizing traditional methods by offering enhanced female-friendly benefits as well as highly accurate1, efficient and timely diagnoses in- office for providers.

As we continue our HyFoSy Global Educational Tour, we are happy to announce our exhibition debut at the 21st annual meeting of the Midwest Reproductive Society international (MRSi) to be held at the Drake Hotel in Chicago, Illinois from June 8th to the 10th. Visit us at Booth #25.

Clinical and Sales team members will be available to guide you through a hands-on experience, teaching you the quick and easy steps to constitute ExEm® Foam, optimal scanning techniques and how to make an assessment, with the distinct and highly echogenic images produced by the ExEm® Foam contrast media.

Visit us at Booth #25 to learn more about:

  • Female-friendly benefits
  • Highly accurate1 and efficient diagnostic readings done in-clinic
  • Clinical in-service training and implementation program
  • HyFoSy ultrasound imaging samples
  • Product samples

About the Midwest Reproductive Symposium international (MRSi)

Reproductive Symposium international (MRSi), is an educational event that began in 2003 to promote the timely discussion of issues relevant to reproductive medicine. The primary objective is the provision of high quality, appropriate, continuing medical education for physicians, nurses, allied health professionals, scientists, and business experts engaged in the practice of and research in reproductive medicine. MRSi’s main event is a 3-day symposium consisting of a mix of lectures, panel discussions and interactive workshops.

MRSi’s mission is to provide an exceptional forum for the multi-disciplinary exploration and discussion of current and emerging issues in reproductive medicine. Through the provision of high quality continuing medical education for all professionals in reproductive medicine – physicians nurses, scientists, mental healthcare providers, business and financial directors – MRSi seeks to stimulate the exchange of perspectives and both enlarge and sharpen the vision for optimal patient care and outcomes.

To learn more about MRSi, visit: https://www.mrsimeeting.org/conference

About ExEm® Foam (air polymer-type A) intrauterine foam
ExEm® Foam ((air polymer-type A) intrauterine foam) is an innovative, FDA-approved product for use in the hysterosalpingo foam sonography (or the HyFoSy). The HyFoSy Procedure is a gentle ultrasound tubal patency assessment for women with known or suspected infertility. During the HyFoSy procedure, ExEm® Foam is infused into the uterus by a healthcare professional and scanned via ultrasound technology to produce a highly echogenic visual assessment of fallopian tubes. If the tubes are patent the foam will be visualized through ultrasound as a thin, bright white line within the fallopian tubes, and will spill over the ovaries and into the peritoneal. If the white line does not appear, the fallopian tubes might be occluded or blocked.

 IMPORTANT SAFETY INFORMATION
ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.

Click here for full prescribing information.

‍About ExEm® Foam Inc
ExEm® Foam Inc is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm® Foam has been used in more than 1,000,000 tubal patency procedures worldwide since it first launched in Europe in 2011. ExEm® Foam Inc. is headquartered in Nashville, TN.

For more information, please visit www.exemfoam.com.

  1. 2020 Wall D, Reinhold C, Akin E, Ascher S, Brook O, Dassel M, Henrichsen T, Learman L, Maturen K, Patlas M,  Robbins J, Sadowski E, Saphier C, Uyeda J, Glanc P. ACR Appropriateness Criteria® Female Infertility. American College of Radiology 2020;  https://doi.org/10.1016/J.JACR.2020.01.018